FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.

Chana Weinstock(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), James Xu(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Geoffrey Kim(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), V. Ellen Maher(United States Food and Drug Administration), Lijun Zhang(Dalian Medical University), Amna Ibrahim(Beni-Suef University)
Journal of Clinical Oncology
May 20, 2016
10.1200/jco.2016.34.15_suppl.4508
Cited by 8

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861